Favorable US court ruling for Teva’s exclusivity on generic Celebrex

31 May 2014

Israel-based Teva Pharmaceutical Industries (NYSE: TEVA) received positive news on Friday, when the US District Court for the Northern District of West Virginia denied a motion filed by US generic drugmaker Mylan (Nasdaq: MYL).

The Court issued an opinion and order affirming a decision by the Food and Drug Administration under which Teva should receive sole 180-day “first-to-file” exclusivity for generic Celebrex (celecoxib) 100mg, 200mg and 400mg capsules.

Last month, Teva entered into a settlement agreement with Pfizer (NYSE: PFE) related to Teva’s generic version of the pharma giant’s blockbuster pain killer/arthritis drug Celebrex capsules in the USA. Under the terms of the settlement, Teva may launch its generic versions in December 2014, or earlier under certain circumstances.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK